The Supreme Court of the United States engaged in a pivotal discussion on March 26, 2024, regarding the FDA's stance on mifepristone, a medication used for abortion. Central to the debate was the FDA's decision to allow the drug to be dispensed without an in-person visit, a move that has sparked significant controversy.

During the meeting, a key point raised was the potential risks associated with eliminating the in-person dispensing requirement. Critics argued that this change could lead to mistakes in gestational aging, potentially resulting in increased medical complications. However, FDA representatives countered that the data did not support the notion that removing the in-person requirement would elevate the risk of serious adverse events, such as death or severe complications requiring transfusions.

The FDA emphasized that even prior to the 2021 changes, ultrasounds were not mandated for prescribing mifepristone. Instead, medical professionals relied on patient history and screening questions to assess risks, such as previous ectopic pregnancies or unusual bleeding. This approach, they argued, aligns with global standards for medication abortions, where ultrasounds are often not a prerequisite.

The discussion highlighted the FDA's confidence in the safety of mifepristone's current dispensing protocols, asserting that there has been no substantial evidence introduced to challenge their 2021 conclusions. As the court deliberates, the implications of this case could significantly impact access to abortion medication across the United States, with potential consequences for women's health care practices moving forward.